{
    "clinical_study": {
        "@rank": "43678", 
        "arm_group": [
            {
                "arm_group_label": "Prasugrel 60 mg", 
                "arm_group_type": "Experimental", 
                "description": "Prasugrel 60 mg as loading dose and followed by 10 mg/day as maintenance dose"
            }, 
            {
                "arm_group_label": "Ticagrelor 180 mg", 
                "arm_group_type": "Experimental", 
                "description": "Ticagrelor 180 mg as loading dose and followed by 90 mg twice a day as maintenance dose"
            }
        ], 
        "brief_summary": {
            "textblock": "To compare efficacy and safety of prasugrel and ticagrelor in patients with ST-segment\n      elevation myocardial infarction undergoing primary percutaneous coronary intervention."
        }, 
        "brief_title": "Prasugrel and Ticagrelor in ST-segment Elevation Myocardial Infarction", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "ST-Segment Elevation Myocardial Infarction", 
        "condition_browse": {
            "mesh_term": [
                "Infarction", 
                "Myocardial Infarction"
            ]
        }, 
        "detailed_description": {
            "textblock": "Prasugrel and ticagrelor are recommended in patients with ST-segment elevation myocardial\n      infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). Both\n      prasugrel and ticagrelor show more rapid and potent antiplatelet effect compared with\n      clopidogrel. However, previous report comparing the efficacy and safety of prasugrel and\n      ticagrelor in patients with STEMI of East Asian ethnicity is lacking. Therefore, the aim of\n      this study is to compare the antiplatelet efficacy and safety using laboratory platelet\n      function tests and clinical outcomes in patients with STEMI treated with either prasugrel or\n      ticagrelor."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with ST-segment elevation myocardial infarction\n\n          -  Undergoing primary PCI\n\n          -  Aged between 20 and 80 years\n\n        Exclusion Criteria\n\n          -  History of stroke or transient ischemic attack\n\n          -  Previous gastrointestinal bleeding within 6 months\n\n          -  Bleeding diathesis\n\n          -  Previous antiplatelet agent administrated\n\n          -  Pre-procedural glycoprotein (Gp) IIb/IIIa inhibitors used (<24 hours)\n\n          -  Chronic oral anticoagulation treatment\n\n          -  Contraindication to the antiplatelet treatment\n\n          -  Hemoglobin < 10 g/dl\n\n          -  Platelet count < 100,000/mm3\n\n          -  Severe renal insufficiency (serum creatine>2.5 mg/dl)\n\n          -  Severe hepatic dysfunction (serum liver enzyme or bilirubin>3 times normal limit)\n\n          -  Sever chronic obstructive pulmonary disease (COPD) or bradycardia\n\n          -  Body weight < 50 kg"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 20, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02075125", 
            "org_study_id": "PANTASTIC"
        }, 
        "intervention": [
            {
                "arm_group_label": "Prasugrel 60 mg", 
                "description": "Patient administer prasugrel 60 mg as loading dose followed by 10 mg/day as maintenance dose.", 
                "intervention_name": "Prasugrel 60 mg", 
                "intervention_type": "Drug", 
                "other_name": "Effient 60 mg"
            }, 
            {
                "arm_group_label": "Ticagrelor 180 mg", 
                "description": "Patients administer ticagrelor 180 mg as loading dose followed by 90 mg bid as maintenance dose.", 
                "intervention_name": "Ticagrelor 180 mg", 
                "intervention_type": "Drug", 
                "other_name": "Brilinta 180 mg"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Prasugrel", 
                "Ticagrelor"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "ST-segment elevation myocardial infarction", 
            "Prasugrel", 
            "Ticagrelor", 
            "Platelet function test"
        ], 
        "lastchanged_date": "February 26, 2014", 
        "location": {
            "contact": {
                "email": "kimmh@dau.ac.kr", 
                "last_name": "Moo Hyun Kim, M.D.", 
                "phone": "+82-51-240-2976"
            }, 
            "facility": {
                "address": {
                    "city": "Busan", 
                    "country": "Korea, Republic of", 
                    "zip": "602-715"
                }, 
                "name": "DongA University Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Comparison of Prasugrel and Ticagrelor Antiplatelet Effects in Korean Patients Presenting With ST-segment Elevation Myocardial Infarction", 
        "overall_contact": {
            "email": "kimmh@dau.ac.kr", 
            "last_name": "Moo Hyun Kim, M.D.", 
            "phone": "+82-51-240-2976"
        }, 
        "overall_official": {
            "affiliation": "Dong-A University Hospital, Busan, Republic of Korea", 
            "last_name": "Moo Hyun Kim, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Platelet reactivity will be measured using VerifyNow (Accumetrics, San Diego, CA, USA) and vasodilator-stimulated phosphoprotein (VASP) phosphorylation. VASP/P2Y12 assay (BioCytex, Marseille, France) and FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, USA) will be used. Measurement time gap +/- 12 hours will be allowed. High on-Treatment Platelet Reactivity (HTPR) is defined as the result of platelet reaction unit (PRU) \u2265242 and vasodilator-stimulated phosphoprotein (VASP) index \u226550%.", 
            "measure": "High on-Treatment Platelet Reactivity", 
            "safety_issue": "No", 
            "time_frame": "48 hours after PCI"
        }, 
        "reference": [
            {
                "PMID": "23500251", 
                "citation": "Parodi G, Valenti R, Bellandi B, Migliorini A, Marcucci R, Comito V, Carrabba N, Santini A, Gensini GF, Abbate R, Antoniucci D. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol. 2013 Apr 16;61(15):1601-6. doi: 10.1016/j.jacc.2013.01.024. Epub 2013 Mar 22."
            }, 
            {
                "PMID": "23169985", 
                "citation": "Alexopoulos D, Xanthopoulou I, Gkizas V, Kassimis G, Theodoropoulos KC, Makris G, Koutsogiannis N, Damelou A, Tsigkas G, Davlouros P, Hahalis G. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv. 2012 Dec;5(6):797-804. doi: 10.1161/CIRCINTERVENTIONS.112.972323. Epub 2012 Nov 20."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02075125"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Dong-A University", 
            "investigator_full_name": "Moo Hyun Kim", 
            "investigator_title": "M.D. Director, Regional Clinical Trial Center. Professor, Dept. of Cardiology Dong-A Unicersity Hospital", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Any MACE including (death, myocardial infarction, stroke, and revascularization procedure with PCI or CABG) until day 30.", 
                "measure": "Major Adverse Cardiovascular Events", 
                "safety_issue": "Yes", 
                "time_frame": "30 days"
            }, 
            {
                "description": "Any event related to bleeding including access site bleeding and peri-procedural bleeding based on BARC criteria.", 
                "measure": "Bleeding event", 
                "safety_issue": "Yes", 
                "time_frame": "30 days"
            }, 
            {
                "description": "Any adverse reaction related to study drug until 30 days after PCI.", 
                "measure": "Adverse drug reaction", 
                "safety_issue": "Yes", 
                "time_frame": "30 days"
            }, 
            {
                "description": "Platelet reactivity will be measured using VerifyNow (Accumetrics, San Diego, CA, USA) and vasodilator-stimulated phosphoprotein (VASP) phosphorylation. VASP/P2Y12 assay (BioCytex, Marseille, France) and FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, USA) will be used. High on-Treatment Platelet Reactivity (HTPR) is defined as the result of platelet reaction unit (PRU) \u2265242 and vasodilator-stimulated phosphoprotein (VASP) index \u226550%.", 
                "measure": "Pre-procedure platelet reactivity", 
                "safety_issue": "No", 
                "time_frame": "Baseline"
            }, 
            {
                "description": "Platelet reactivity will be measured using VerifyNow (Accumetrics, San Diego, CA, USA) and vasodilator-stimulated phosphoprotein (VASP) phosphorylation. VASP/P2Y12 assay (BioCytex, Marseille, France) and FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, USA) will be used. High on-Treatment Platelet Reactivity (HTPR) is defined as the result of platelet reaction unit (PRU) \u2265242 and vasodilator-stimulated phosphoprotein (VASP) index \u226550%.", 
                "measure": "Platelet reactivity", 
                "safety_issue": "No", 
                "time_frame": "30 days"
            }
        ], 
        "source": "Dong-A University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Dong-A University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}